What is it about?
We conducted a NNT analysis on a RCT datapool of 636 patients, treated with either low dose, high dose palmitoylethanolamide or placebo. The NNT was 1.5 for high dose. We also reviewed all preclinical and clinical work on palmitoylethanolamide in nerve compression syndromes such as sciatica and carpal tunnel syndrome. In all studies a consistent message appears: PEA is safe and effective in chronic pain states due to nerve compression. PEA should be used more frequently, especially since it is easily available as a food supplement (400 mg capsules).
Featured Image
Why is it important?
It is important because there are only few good analgesics with excellent tolerability and safety, and no drug-drug interactions. Palmitoylethanolamide creates a new dimension in treating chronic pain.
Perspectives
In the medical discours pain physicians should start realizing that supplements can contribute significantly to pain medicine. As Palmitoylethanolamide triggers endogenous repair mechanisms and helps to quiet down overactive glia, it will be discovered more and more as a new analgesic principle. PEA will become a fundament for the new medicine of the 21th century, the Autacoid Medicine.
jan keppel hesselink
Institute Neuropathic Pain
Read the Original
This page is a summary of: Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome, Journal of Pain Research, October 2015, Dove Medical Press,
DOI: 10.2147/jpr.s93106.
You can read the full text:
Resources
Contributors
The following have contributed to this page
